<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><atom:link href="https://da.cosperpharma.com/rss.xml" rel="self" type="application/rss+xml" /><title><![CDATA[Cosper Pharma Tech Co., Ltd.]]></title><category><![CDATA[Cosper Pharma Tech Co., Ltd.]]></category><description><![CDATA[Cosper er en betroet kinesisk farmaceutisk producent, der tilbyder CRO/CDMO-tjenester, API'er og mellemprodukter. GMP-certificeret fabrik med fuld kæde levering fra R&D til produktion. Kontakt os nu.]]></description><link><![CDATA[https://da.cosperpharma.com]]></link><language>da</language><pubDate>Thu, 15 Oct 2026 01:58:12 GMT</pubDate><lastBuildDate>Thu, 15 Oct 2026 01:58:12 GMT</lastBuildDate><item><title><![CDATA[Synteserute af Mitapivat]]></title><link><![CDATA[https://da.cosperpharma.com/news/synthesis-route-of-mitapivat.html]]></link><guid isPermaLink="false">news-1100</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Syntesevej af Mitapivat]]></description><pubDate><![CDATA[Wed, 30 Sep 2026 07:37:59 GMT]]></pubDate></item><item><title><![CDATA[Ropivacaine Hydrochloride: En n&#248;gle lokalbed&#248;vende API til farmaceutisk fremstilling]]></title><link><![CDATA[https://da.cosperpharma.com/news/ropivacaine-hydrochloride-a-key-local-anesthetic-api-for-pharmaceutical-manufacturing.html]]></link><guid isPermaLink="false">news-1097</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Ropivacaine Hydrochloride: Et nøgle API til lokalbedøvelse til farmaceutisk fremstilling]]></description><pubDate><![CDATA[Tue, 29 Sep 2026 09:58:51 GMT]]></pubDate></item><item><title><![CDATA[Upadacitinib Intermediates Supply]]></title><link><![CDATA[https://da.cosperpharma.com/news/upadacitinib-intermediates-supply.html]]></link><guid isPermaLink="false">news-1094</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Upadacitinib-mellemprodukter]]></description><pubDate><![CDATA[Mon, 21 Sep 2026 08:18:37 GMT]]></pubDate></item><item><title><![CDATA[Finerenone Mellemforsyning]]></title><link><![CDATA[https://da.cosperpharma.com/news/finerenone-intermediates-supply.html]]></link><guid isPermaLink="false">news-1091</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Finerenone-mellemprodukter]]></description><pubDate><![CDATA[Mon, 21 Sep 2026 08:18:59 GMT]]></pubDate></item><item><title><![CDATA[Conivaptan Mellemforsyning]]></title><link><![CDATA[https://da.cosperpharma.com/news/conivaptan-intermediates-supply.html]]></link><guid isPermaLink="false">news-1088</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Conivaptan-mellemprodukter]]></description><pubDate><![CDATA[Mon, 21 Sep 2026 08:19:15 GMT]]></pubDate></item><item><title><![CDATA[Tolvaptan Mellemforsyning]]></title><link><![CDATA[https://da.cosperpharma.com/news/tolvaptan-intermediates-supply.html]]></link><guid isPermaLink="false">news-1083</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Tolvaptan-mellemprodukter]]></description><pubDate><![CDATA[Mon, 21 Sep 2026 08:10:24 GMT]]></pubDate></item><item><title><![CDATA[Midazolam Mellemprodukter Forsyning]]></title><link><![CDATA[https://da.cosperpharma.com/news/midazolam-intermediates-supply.html]]></link><guid isPermaLink="false">news-1078</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Midazolam-mellemprodukter]]></description><pubDate><![CDATA[Mon, 21 Sep 2026 08:07:32 GMT]]></pubDate></item><item><title><![CDATA[Darolutamid Mellemprodukter Forsyning]]></title><link><![CDATA[https://da.cosperpharma.com/news/darolutamide-intermediates-supply.html]]></link><guid isPermaLink="false">news-1071</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Darolutamid-mellemprodukter]]></description><pubDate><![CDATA[Mon, 21 Sep 2026 08:04:25 GMT]]></pubDate></item><item><title><![CDATA[Aromatiske ringe og aromatiske heterocykliske systemer Forsyning]]></title><link><![CDATA[https://da.cosperpharma.com/news/aromatic-rings-and-aromatic-heterocyclic-systems-supply.html]]></link><guid isPermaLink="false">news-1064</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd. : Aromatiske ringe og aromatiske heterocykliske systemer Levering]]></description><pubDate><![CDATA[Wed, 16 Sep 2026 08:10:22 GMT]]></pubDate></item><item><title><![CDATA[Langk&#230;dede alkylalkoholer og ketoner Levering]]></title><link><![CDATA[https://da.cosperpharma.com/news/long-chain-alkyl-alcohols-ketones-supply.html]]></link><guid isPermaLink="false">news-1057</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Levering af langkædede alkylalkoholer og ketoner]]></description><pubDate><![CDATA[Wed, 16 Sep 2026 08:12:58 GMT]]></pubDate></item><item><title><![CDATA[Enzalutamid og mellemprodukter levering]]></title><link><![CDATA[https://da.cosperpharma.com/news/enzalutamide-and-intermediates-supply.html]]></link><guid isPermaLink="false">news-1050</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Levering af enzalutamid og mellemprodukter]]></description><pubDate><![CDATA[Tue, 15 Sep 2026 06:00:18 GMT]]></pubDate></item><item><title><![CDATA[Bicalutamide mellemprodukter levering]]></title><link><![CDATA[https://da.cosperpharma.com/news/bicalutamide-intermediates-supply.html]]></link><guid isPermaLink="false">news-1033</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Bicalutamid-mellemprodukter]]></description><pubDate><![CDATA[Tue, 15 Sep 2026 02:49:31 GMT]]></pubDate></item><item><title><![CDATA[Lurasidon Mellemprodukter Forsyning]]></title><link><![CDATA[https://da.cosperpharma.com/news/lurasidone-intermediates-supply.html]]></link><guid isPermaLink="false">news-1024</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Levering af lurasidonmellemprodukter]]></description><pubDate><![CDATA[Tue, 15 Sep 2026 01:38:32 GMT]]></pubDate></item><item><title><![CDATA[Pregabalin mellemprodukter levering]]></title><link><![CDATA[https://da.cosperpharma.com/news/pregabalin-intermediates-supply.html]]></link><guid isPermaLink="false">news-1019</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Pregabalin-mellemprodukter]]></description><pubDate><![CDATA[Fri, 11 Sep 2026 09:01:40 GMT]]></pubDate></item><item><title><![CDATA[Daraxonrasib (RMC-6236) Fuld serie af mellemprodukter]]></title><link><![CDATA[https://da.cosperpharma.com/news/daraxonrasib-rmc-6236-full-series-of-intermediates-supply.html]]></link><guid isPermaLink="false">news-1012</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Daraxonrasib (RMC-6236) komplet serie af mellemprodukter]]></description><pubDate><![CDATA[Fri, 11 Sep 2026 01:56:06 GMT]]></pubDate></item><item><title><![CDATA[MK-0616 (Enlicitide) Fuld serie af mellemprodukter]]></title><link><![CDATA[https://da.cosperpharma.com/news/full-series-of-intermediates-for-mk-0616-enlicitide-supply.html]]></link><guid isPermaLink="false">news-1004</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: MK-0616 (Enlicitide) komplet serie af mellemprodukter]]></description><pubDate><![CDATA[Fri, 11 Sep 2026 01:50:38 GMT]]></pubDate></item><item><title><![CDATA[Nerandomilast (BI-1015550) Fuld serie af mellemprodukter]]></title><link><![CDATA[https://da.cosperpharma.com/news/nerandomilast-bi-1015550-full-series-of-intermediates-supply.html]]></link><guid isPermaLink="false">news-999</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Nerandomilast (BI-1015550) komplet serie af mellemprodukter]]></description><pubDate><![CDATA[Thu, 10 Sep 2026 03:13:00 GMT]]></pubDate></item><item><title><![CDATA[Zavegepant fuld serie af mellemprodukter]]></title><link><![CDATA[https://da.cosperpharma.com/news/zavegepant-full-series-of-intermediates-supply.html]]></link><guid isPermaLink="false">news-991</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Zavegepant fuld serie af mellemprodukter]]></description><pubDate><![CDATA[Wed, 09 Sep 2026 01:31:54 GMT]]></pubDate></item><item><title><![CDATA[Finerenone og fuld serie af mellemprodukter]]></title><link><![CDATA[https://da.cosperpharma.com/news/finerenone-and-full-series-of-intermediates-supply.html]]></link><guid isPermaLink="false">news-984</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Finerenon og fuld serie af mellemprodukter]]></description><pubDate><![CDATA[Tue, 08 Sep 2026 01:15:00 GMT]]></pubDate></item><item><title><![CDATA[Osimertinib og fuld serie af mellemprodukter]]></title><link><![CDATA[https://da.cosperpharma.com/news/osimertinib-and-full-series-of-intermediates-supply.html]]></link><guid isPermaLink="false">news-976</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Osimertinib og fuld serie af mellemprodukter]]></description><pubDate><![CDATA[Mon, 07 Sep 2026 07:14:33 GMT]]></pubDate></item><item><title><![CDATA[Produktforsyning | Tenapanor API, dets mellemprodukter og urenheder API-oplysninger]]></title><link><![CDATA[https://da.cosperpharma.com/news/product-supply-tenapanor-api-its-intermediates-and-impurities-api-information.html]]></link><guid isPermaLink="false">news-970</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd. : Produktforsyning | Tenapanor API, dets mellemprodukter og urenheder API-oplysninger]]></description><pubDate><![CDATA[Thu, 03 Sep 2026 03:45:51 GMT]]></pubDate></item><item><title><![CDATA[Syntetisk rute for Linerixibat]]></title><link><![CDATA[https://da.cosperpharma.com/news/synthetic-route-of-linerixibat.html]]></link><guid isPermaLink="false">news-963</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Syntetisk rute for Linerixibat]]></description><pubDate><![CDATA[Wed, 02 Sep 2026 07:37:57 GMT]]></pubDate></item><item><title><![CDATA[Arbidol Mellemforsyning fra Cosperpharm]]></title><link><![CDATA[https://da.cosperpharma.com/news/arbidol-intermediates-supply-by-cosperpharm.html]]></link><guid isPermaLink="false">news-956</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Arbidol-mellemprodukter fra Cosperpharm]]></description><pubDate><![CDATA[Wed, 26 Aug 2026 08:08:07 GMT]]></pubDate></item><item><title><![CDATA[Avexitide (Exendin(9-39) amid) er den hurtigst udviklende GLP-1-receptorantagonist p&#229; verdensplan; det er et line&#230;rt polypeptid sammensat af 31 aminosyrer med en C-terminal amidmodifikation.]]></title><link><![CDATA[https://da.cosperpharma.com/news/avexitide-exendin-9-39-amide-is-the-fastest-developing-glp-1-receptor-antagonist-worldwide-it-is-a-linear-polypeptide-composed-of-31-amino-acids-with-a-c-terminal-amide-modification.html]]></link><guid isPermaLink="false">news-948</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Avexitide (Exendin(9-39)-amid) er den hurtigst udviklende GLP-1-receptorantagonist på verdensplan; det er et lineært polypeptid sammensat af 31 aminosyrer med en C-terminal amidmodifikation.]]></description><pubDate><![CDATA[Fri, 21 Aug 2026 08:40:35 GMT]]></pubDate></item><item><title><![CDATA[Liraglutid: En GLP-1-receptoragonist, der &#248;ger stofskiftet]]></title><link><![CDATA[https://da.cosperpharma.com/news/liraglutide-a-glp-1-receptor-agonist-that-enhances-metabolism.html]]></link><guid isPermaLink="false">news-942</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Liraglutid: En GLP-1-receptoragonist, der øger stofskiftet]]></description><pubDate><![CDATA[Wed, 19 Aug 2026 03:04:33 GMT]]></pubDate></item><item><title><![CDATA[Daridorexant Hydrochloride COA]]></title><link><![CDATA[https://da.cosperpharma.com/news/daridorexant-hydrochloride.html]]></link><guid isPermaLink="false">news-596</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Daridorexant Hydrochloride COA]]></description><pubDate><![CDATA[Fri, 14 Aug 2026 09:47:21 GMT]]></pubDate></item><item><title><![CDATA[Iminesiru for Relebactam]]></title><link><![CDATA[https://da.cosperpharma.com/news/iminesiru-for-relebactam.html]]></link><guid isPermaLink="false">news-593</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Iminesiru for Relebactam]]></description><pubDate><![CDATA[Fri, 14 Aug 2026 03:33:50 GMT]]></pubDate></item><item><title><![CDATA[Screeningsunders&#248;gelse af trofinetide cokrystalform]]></title><link><![CDATA[https://da.cosperpharma.com/news/screening-study-of-trofinetide-cocrystal-form.html]]></link><guid isPermaLink="false">news-590</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Screeningsundersøgelse af trofinetide cokrystal‌form]]></description><pubDate><![CDATA[Wed, 12 Aug 2026 02:38:02 GMT]]></pubDate></item><item><title><![CDATA[JACS: Merck har indg&#229;et et samarbejde med Huanquan og Conquer Biotech for at offentligg&#248;re den samlede synteseproces for MK-0616.]]></title><link><![CDATA[https://da.cosperpharma.com/news/jacs-merck-has-partnered-with-huanquan-and-conquer-biotech-to-publicly-disclose-the-total-synthesis-process-for-mk-0616.html]]></link><guid isPermaLink="false">news-587</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: JACS: Merck har indgået partnerskab med Huanquan og Conquer Biotech for at offentliggøre den samlede synteseproces for MK-0616.]]></description><pubDate><![CDATA[Mon, 10 Aug 2026 09:50:59 GMT]]></pubDate></item><item><title><![CDATA[Hvordan skal chelateringsmidler udv&#230;lges til m&#229;lrettede radionuklider?]]></title><link><![CDATA[https://da.cosperpharma.com/news/how-should-chelating-agents-be-selected-for-targeted-radionuclides.html]]></link><guid isPermaLink="false">news-584</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Hvordan skal chelateringsmidler udvælges til målrettede radionuklider?]]></description><pubDate><![CDATA[Wed, 05 Aug 2026 09:17:22 GMT]]></pubDate></item><item><title><![CDATA[Eutektisk teknologi: &#197;bner d&#248;ren til forskning og udvikling af nye l&#230;gemidler og modificerede l&#230;gemidler]]></title><link><![CDATA[https://da.cosperpharma.com/news/eutectic-technology-opening-the-door-to-new-drug-and-modified-drug-r-d.html]]></link><guid isPermaLink="false">news-580</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd. : Eutektisk teknologi: Åbner døren til forskning og udvikling af nye lægemidler og modificerede lægemidler]]></description><pubDate><![CDATA[Tue, 04 Aug 2026 03:03:10 GMT]]></pubDate></item><item><title><![CDATA[Farmaceutisk mellemliggende information]]></title><link><![CDATA[https://da.cosperpharma.com/news/pharmaceutical-intermediate-information.html]]></link><guid isPermaLink="false">news-478</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Farmaceutisk mellemliggende information]]></description><pubDate><![CDATA[Tue, 28 Jul 2026 03:47:46 GMT]]></pubDate></item><item><title><![CDATA[Analyse af synteseprocessen for Eli Lillys n&#248;glel&#230;gemiddel: Tirzepatid]]></title><link><![CDATA[https://da.cosperpharma.com/news/analysis-of-the-synthesis-process-for-eli-lilly-s-key-drug-tirzepatide.html]]></link><guid isPermaLink="false">news-474</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Analyse af synteseprocessen for Eli Lillys nøglelægemiddel: Tirzepatid]]></description><pubDate><![CDATA[Mon, 27 Jul 2026 06:52:33 GMT]]></pubDate></item><item><title><![CDATA[Syntetisk rute af trofinetide]]></title><link><![CDATA[https://da.cosperpharma.com/news/synthetic-route-of-trofinetide.html]]></link><guid isPermaLink="false">news-472</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Syntetisk rute for trofinetide]]></description><pubDate><![CDATA[Fri, 24 Jul 2026 08:39:34 GMT]]></pubDate></item><item><title><![CDATA[Fremstillingsmetode for Cagrilintide]]></title><link><![CDATA[https://da.cosperpharma.com/news/preparation-method-of-cagrilintide.html]]></link><guid isPermaLink="false">news-469</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Fremstillingsmetode for Cagrilintide]]></description><pubDate><![CDATA[Thu, 16 Jul 2026 03:36:35 GMT]]></pubDate></item><item><title><![CDATA[Verdens f&#248;rste aktuelle JAK-h&#230;mmer til behandling af &quot;h&#229;ndeksem&quot; - Delgocitinib creme]]></title><link><![CDATA[https://da.cosperpharma.com/news/the-world-s-first-topical-jak-inhibitor-for-treating-hand-eczema-delgocitinib-cream.html]]></link><guid isPermaLink="false">news-465</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Verdens første topiske JAK-hæmmer til behandling af "håndeksem" – Delgocitinib creme]]></description><pubDate><![CDATA[Tue, 14 Jul 2026 05:53:02 GMT]]></pubDate></item><item><title><![CDATA[AI-drevet design af chelatorer til udvikling af nuklear narkotika: udfordringer]]></title><link><![CDATA[https://da.cosperpharma.com/news/ai-driven-design-of-chelators-for-nuclear-drug-development-challenges.html]]></link><guid isPermaLink="false">news-461</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: AI-drevet design af chelatorer til udvikling af nuklear medicin: udfordringer]]></description><pubDate><![CDATA[Fri, 10 Jul 2026 06:25:33 GMT]]></pubDate></item><item><title><![CDATA[Anbefaling for udvikling og syntese af Brexpiprazol]]></title><link><![CDATA[https://da.cosperpharma.com/news/recommendation-for-the-development-and-synthesis-route-of-brexpiprazole.html]]></link><guid isPermaLink="false">news-455</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Anbefaling for udvikling og syntese af Brexpiprazol]]></description><pubDate><![CDATA[Thu, 09 Jul 2026 08:32:44 GMT]]></pubDate></item><item><title><![CDATA[Mirakell&#230;gemidlet mod influenza A – Baloxavir marboxil]]></title><link><![CDATA[https://da.cosperpharma.com/news/the-miracle-drug-for-influenza-a-baloxavir-marboxil.html]]></link><guid isPermaLink="false">news-452</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Mirakellægemidlet mod influenza A – Baloxavir marboxil]]></description><pubDate><![CDATA[Tue, 07 Jul 2026 07:54:05 GMT]]></pubDate></item><item><title><![CDATA[Antiviralt l&#230;gemiddel: Amenamevir]]></title><link><![CDATA[https://da.cosperpharma.com/news/antiviral-drug-amenamevir.html]]></link><guid isPermaLink="false">news-449</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Antiviralt lægemiddel: Amenamevir]]></description><pubDate><![CDATA[Fri, 03 Jul 2026 09:43:22 GMT]]></pubDate></item><item><title><![CDATA[Vibegron: Projektforslag og synteserute]]></title><link><![CDATA[https://da.cosperpharma.com/news/vibegron-project-proposal-and-synthesis-route.html]]></link><guid isPermaLink="false">news-294</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd. : Vibegron: Projektforslag og synteserute]]></description><pubDate><![CDATA[Tue, 30 Jun 2026 08:34:43 GMT]]></pubDate></item><item><title><![CDATA[Oversigt og fremstilling af Icatibant-acetat]]></title><link><![CDATA[https://da.cosperpharma.com/news/overview-and-preparation-of-icatibant-acetate.html]]></link><guid isPermaLink="false">news-293</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Oversigt og fremstilling af Icatibant-acetat]]></description><pubDate><![CDATA[Tue, 30 Jun 2026 08:33:59 GMT]]></pubDate></item><item><title><![CDATA[Uddybende artikel: N-methylering, α-methylering, D-aminosyrer, unaturlige aminosyrer til polypeptid]]></title><link><![CDATA[https://da.cosperpharma.com/news/in-depth-article-n-methylation-methylation-d-amino-acids-unnatural-amino-acids-for-polypeptide.html]]></link><guid isPermaLink="false">news-292</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Uddybende artikel: N-methylering, α-methylering, D-aminosyrer, unaturlige aminosyrer til polypeptid]]></description><pubDate><![CDATA[Tue, 09 Jun 2026 09:55:58 GMT]]></pubDate></item><item><title><![CDATA[Hvorfor er Pralatrexat vigtigt i moderne kr&#230;ftbehandling?]]></title><link><![CDATA[https://da.cosperpharma.com/news/why-is-pralatrexate-important-in-modern-cancer-treatment.html]]></link><guid isPermaLink="false">news-238</guid><description><![CDATA[Pralatrexate er et specialiseret antifolat-kemoterapilægemiddel, der primært anvendes til behandling af recidiverende eller refraktært perifert T-celle lymfom (PTCL). Siden introduktionen er det blevet en vigtig terapeutisk mulighed for patienter, der har begrænsede behandlingsalternativer.]]></description><pubDate><![CDATA[Tue, 02 Jun 2026 06:09:11 GMT]]></pubDate></item><item><title><![CDATA[Hvordan syntetiseres MAAA-1162a?]]></title><link><![CDATA[https://da.cosperpharma.com/news/how-is-maaa-1162a-synthesized.html]]></link><guid isPermaLink="false">news-215</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Hvordan syntetiseres MAAA-1162a?]]></description><pubDate><![CDATA[Fri, 29 May 2026 10:08:20 GMT]]></pubDate></item><item><title><![CDATA[Syntese af doxercalciferol]]></title><link><![CDATA[https://da.cosperpharma.com/news/the-synthesis-of-doxercalciferol.html]]></link><guid isPermaLink="false">news-211</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Syntesen af ​​doxercalciferol]]></description><pubDate><![CDATA[Thu, 28 May 2026 09:36:32 GMT]]></pubDate></item><item><title><![CDATA[Med GLP-1 Regulatory Bars indstillet til en 0,1 % identifikationst&#230;rskel, er din saccharoseoctasulfat-aluminiumkompleks (Orforglipron Urenhed 18) referencestandard robust nok til tvungen nedbrydning og ANDA-arkivering?]]></title><link><![CDATA[https://da.cosperpharma.com/news/with-glp-1-regulatory-bars-set-at-a-0-1-identification-threshold-is-your-sucrose-octasulfate-aluminum-complex-orforglipron-impurity-18-reference-standard-robust-enough-for-forced-degradation-and-anda-filing.html]]></link><guid isPermaLink="false">news-203</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Med GLP-1 regulatoriske barer sat til en 0,1 % identifikationstærskel, er din saccharoseoctasulfat-aluminiumkompleks (Orforglipron Urenhed 18) referencestandard robust nok til tvungen nedbrydning og ANDA-arkivering?]]></description><pubDate><![CDATA[Thu, 28 May 2026 03:17:40 GMT]]></pubDate></item><item><title><![CDATA[Hvordan forvandler Migalastat Fabrys sygdomsbehandling?]]></title><link><![CDATA[https://da.cosperpharma.com/news/how-does-migalastat-transform-fabry-disease-treatment.html]]></link><guid isPermaLink="false">news-156</guid><description><![CDATA[Migalastat er en innovativ oral terapi designet til behandling af Fabrys sygdom, en sjælden genetisk lysosomal lagringsforstyrrelse, der påvirker flere organer og reducerer livskvaliteten betydeligt. I modsætning til traditionelle enzymerstatningsterapier virker Migalastat ved at stabilisere visse former for kroppens eget enzym, så det kan fungere mere effektivt.]]></description><pubDate><![CDATA[Tue, 26 May 2026 02:25:14 GMT]]></pubDate></item><item><title><![CDATA[Biokatalytiske kaskader muligg&#248;r fremstilling af det makrocykliske peptid Enlicitide]]></title><link><![CDATA[https://da.cosperpharma.com/news/biocatalytic-cascades-enable-the-manufacturing-of-the-macrocyclic-peptide-enlicitide.html]]></link><guid isPermaLink="false">news-155</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Biokatalytiske kaskader muliggør fremstilling af det makrocykliske peptid Enlicitide]]></description><pubDate><![CDATA[Thu, 21 May 2026 09:36:41 GMT]]></pubDate></item><item><title><![CDATA[Hvad g&#248;r Osimertinib til en banebrydende terapi til moderne lungekr&#230;ftbehandling?]]></title><link><![CDATA[https://da.cosperpharma.com/news/what-makes-osimertinib-a-breakthrough-therapy-for-modern-lung-cancer-treatment.html]]></link><guid isPermaLink="false">news-78</guid><description><![CDATA[Osimertinib har transformeret behandlingslandskabet for patienter med ikke-småcellet lungekræft (NSCLC), især dem, der bærer EGFR-mutationer. Sammenlignet med traditionel kemoterapi tilbyder denne målrettede terapi forbedrede overlevelsesrater, bedre hjernepenetration og færre alvorlige systemiske toksiciteter. Imidlertid står mange patienter og sundhedskøbere stadig over for spørgsmål vedrørende effektivitet, sikkerhed, modstandsmekanismer, overkommelighed og langsigtede resultater.]]></description><pubDate><![CDATA[Mon, 18 May 2026 03:09:49 GMT]]></pubDate></item><item><title><![CDATA[Hvad g&#248;r Sapropterin vigtigt til styring af PKU?]]></title><link><![CDATA[https://da.cosperpharma.com/news/what-makes-sapropterin-important-for-managing-pku.html]]></link><guid isPermaLink="false">news-77</guid><description><![CDATA[Sapropterin er blevet en vigtig terapeutisk mulighed for personer, der lever med phenylketonuri (PKU), især patienter, der bevarer en vis resterende phenylalaninhydroxylaseaktivitet. Denne medicin hjælper med at reducere phenylalaninniveauet i blodet, hvilket muliggør forbedret metabolisk kontrol og potentielt en mindre restriktiv diæt for visse patienter.]]></description><pubDate><![CDATA[Wed, 13 May 2026 05:49:25 GMT]]></pubDate></item><item><title><![CDATA[Hvad er pralatrexat?]]></title><link><![CDATA[https://da.cosperpharma.com/news/what-is-pralatrexate.html]]></link><guid isPermaLink="false">news-76</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Hvad er pralatrexat?]]></description><pubDate><![CDATA[Mon, 11 May 2026 07:02:10 GMT]]></pubDate></item><item><title><![CDATA[Hvad er Zanubrutinib?]]></title><link><![CDATA[https://da.cosperpharma.com/news/what-is-zanubrutinib.html]]></link><guid isPermaLink="false">news-75</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Hvad er Zanubrutinib?]]></description><pubDate><![CDATA[Mon, 11 May 2026 07:02:50 GMT]]></pubDate></item><item><title><![CDATA[Hvad er virkningerne og virkningen af ​​carfilzomib?]]></title><link><![CDATA[https://da.cosperpharma.com/news/what-are-the-effects-and-efficacy-of-carfilzomib.html]]></link><guid isPermaLink="false">news-74</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Hvad er virkningerne og virkningen af ​​carfilzomib?]]></description><pubDate><![CDATA[Mon, 11 May 2026 07:03:43 GMT]]></pubDate></item><item><title><![CDATA[Hvad er utpatinib?]]></title><link><![CDATA[https://da.cosperpharma.com/news/what-is-utpatinib.html]]></link><guid isPermaLink="false">news-73</guid><description><![CDATA[Cosper Pharma Tech Co., Ltd.: Hvad er utpatinib?]]></description><pubDate><![CDATA[Mon, 11 May 2026 07:04:21 GMT]]></pubDate></item></channel></rss>